Eklavya Biotech Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 25-06-2024
- Paid Up Capital ₹ 0.10 M
as on 25-06-2024
- Company Age 7 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 253.33%
(FY 2020)
- Profit -3514.29%
(FY 2020)
- Ebitda -2544.86%
(FY 2020)
- Net Worth -2359.49%
(FY 2020)
- Total Assets 86.20%
(FY 2020)
About Eklavya Biotech
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Nirmal Naagar, Dibiya Sahani, and Virendra Nishad serve as directors at the Company.
- CIN/LLPIN
U51909MH2017PTC294885
- Company No.
294885
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 May 2017
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Eklavya Biotech Private Limited offer?
Eklavya Biotech Private Limited offers a wide range of products and services, including Fertilizers and Soil Additives, Organic Fertilizers and Manure, Nutraceuticals & Dietary Supplements, Mineral Supplement, Cooking Spices and Masala, Saffron, Bird Food, Poultry & Animal Food, Animal Feed, Fresh, Dried & Preserved Vegetables, Mushroom.
Who are the key members and board of directors at Eklavya Biotech?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nirmal Naagar  | Director | 16-May-2017 | Current |
| Dibiya Sahani | Director | 16-May-2017 | Current |
| Virendra Nishad | Director | 24-May-2023 | Current |
Financial of Eklavya Biotech.
Eklavya Biotech Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 253.33% increase. The company also saw a substantial fall in profitability, with a 3514.29% decrease in profit. The company's net worth observed a substantial decline by a decrease of 2359.49%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Eklavya Biotech?
In 2019, Eklavya Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Eklavya Biotech?
Unlock and access historical data on people associated with Eklavya Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Eklavya Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Eklavya Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
